MRUS

Merus N.V. Healthcare - Biotechnology Investor Relations →

NO
127.8% ABOVE
↓ Approaching Was 147.3% last week
-15% -10% -5% 0% 5% 10% 15%+
Buy Threshold $39.51
14-Week RSI 80

Merus N.V. (MRUS) closed at $90.00 as of 2025-12-29, trading 127.8% above its 200-week moving average of $39.51. The stock is currently moving closer to the line, down from 147.3% last week. With a 14-week RSI of 80, MRUS is in overbought territory.

Over the past 454 weeks of data, MRUS has crossed below its 200-week moving average 16 times. On average, these episodes lasted 10 weeks. Historically, investors who bought MRUS at the start of these episodes saw an average one-year return of +46.8%.

With a market cap of $6.8 billion, MRUS is a mid-cap stock. Free cash flow yield is currently negative, meaning the company is burning cash. Return on equity stands at -51.6%. The stock trades at 8.8x book value.

Share count has increased 58.3% over three years, indicating dilution.

Over the past 8.8 years, a hypothetical investment of $100 in MRUS would have grown to $405, compared to $328 for the S&P 500. That represents an annualized return of 17.3% vs 14.6% for the index — confirming MRUS as a market-beating investment and the kind of quality company where buying during 200-week moving average touches has historically been rewarded.

In the past 12 months, corporate insiders have made 3 open-market purchases totaling $132,446,904. Multiple insiders purchased within a 30-day window — a cluster buy pattern that historically signals management confidence in the company's prospects.

Free cash flow has been declining. A deteriorating cash flow trend warrants extra scrutiny — the stock may be cheap for a reason.

Growth of $100: MRUS vs S&P 500

Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.

What Happens After MRUS Crosses Below the Line?

Across 16 historical episodes, buying MRUS when it crossed below its 200-week moving average produced an average return of +48.1% after 12 months (median +44.0%), compared to +19.8% for the S&P 500 over the same periods. 81% of those episodes were profitable after one year. After 24 months, the average return was +85.6% vs +39.9% for the index.

Each line shows $100 invested at the moment MRUS crossed below its 200-week MA. Bold blue = stock average. Gray dashed = S&P 500 average over same periods.

Advertisement

Insider Buying Activity

3 conviction buys in the past 12 months (purchases over $500K with meaningful position increases). 🔥 Cluster Buy Detected

DateInsiderTitleValueSharesPosition +%
2025-12-26GENMAB ASBeneficial Owner of more than 10% of a Class of Security$79,098,068815,444+1.1%
2025-12-19GENMAB ASBeneficial Owner of more than 10% of a Class of Security$27,008,777278,441+0.4%
2025-12-17GENMAB ASBeneficial Owner of more than 10% of a Class of Security$26,340,059271,547+0.4%

Historical Touches

MRUS has crossed below its 200-week MA 16 times with an average 1-year return of +46.8% after recovery.

Crossed BelowRecoveredWeeksMax Depth1-Year ReturnReturn Since Touch
Jun 2017Jul 2017415.1%+22.3%+479.3%
Jul 2017Sep 2017918.4%+42.9%+452.1%
Oct 2017Dec 2017912.5%-14.9%+458.0%
Feb 2018Feb 201814.3%-25.3%+460.0%
Oct 2018Sep 20194834.7%+4.5%+472.9%
Sep 2019Dec 20191010.7%-26.8%+447.4%
Dec 2019Jan 2020318.6%+18.2%+485.6%
Jan 2020Feb 202011.5%+68.3%+450.5%
Mar 2020Nov 20203837.0%+40.8%+453.2%
Dec 2020Dec 202012.9%+89.3%+462.5%
May 2022May 2022313.4%+16.1%+402.2%
Sep 2022Sep 202211.0%+28.2%+381.8%
Oct 2022Mar 20231931.1%+45.8%+427.2%
Mar 2023Apr 202325.7%+144.7%+389.1%
Apr 2023May 202311.9%+134.8%+369.2%
Oct 2023Oct 202321.9%+159.6%+343.3%
Average10+46.8%

Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.

Data as of Friday close, 2025-12-29